NASDAQ:TRVI

Trevi Therapeutics (TRVI) Stock Price, News & Analysis

$2.65
-0.20 (-7.02%)
(As of 04/24/2024 ET)
Today's Range
$2.57
$2.87
50-Day Range
$2.38
$3.70
52-Week Range
$0.97
$4.00
Volume
124,794 shs
Average Volume
276,927 shs
Market Capitalization
$182.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

Trevi Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
220.8% Upside
$8.50 Price Target
Short Interest
Healthy
1.51% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.39) to ($0.46) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.44 out of 5 stars

Medical Sector

455th out of 907 stocks

Pharmaceutical Preparations Industry

208th out of 421 stocks

TRVI stock logo

About Trevi Therapeutics Stock (NASDAQ:TRVI)

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

TRVI Stock Price History

TRVI Stock News Headlines

Global crypto currency reset (41 major banks signed up)
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
Global crypto currency reset (41 major banks signed up)
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
Trevi Therapeutics: Q4 Earnings Insights
Trevi Therapeutics to Participate in Upcoming March Events
Trevi Therapeutics Inc.
TRVI Mar 2024 2.000 call
TRVI Mar 2024 3.000 call
See More Headlines
Receive TRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/20/2024
Today
4/24/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TRVI
Fax
N/A
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.50
High Stock Price Target
$9.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+220.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-29,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.29 per share

Miscellaneous

Free Float
50,024,000
Market Cap
$182.74 million
Optionable
Optionable
Beta
0.86
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Ms. Jennifer L. Good (Age 59)
    Co-Founder, CEO, President & Director
    Comp: $781.85k
  • Dr. Thomas R. Sciascia M.D. (Age 71)
    Co-Founder & Chief Science Officer
    Comp: $530.48k
  • Dr. David J. Clark A.F.P.M. (Age 59)
    M.D., M.R.C.P., Chief Medical Officer
    Comp: $325.39k
  • Ms. Lisa Delfini (Age 54)
    Chief Financial Officer
  • Mr. Christopher Galletta (Age 46)
    Controller & Chief Accounting Officer
  • Katie McManus
    Communications Manager
  • Mr. Farrell Simon Pharm.D.
    Chief Commercial Officer
  • Ms. Danine Summers (Age 66)
    Vice President of Medical Affairs

TRVI Stock Analysis - Frequently Asked Questions

Should I buy or sell Trevi Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TRVI shares.
View TRVI analyst ratings
or view top-rated stocks.

What is Trevi Therapeutics' stock price target for 2024?

2 brokers have issued 12 month price targets for Trevi Therapeutics' stock. Their TRVI share price targets range from $8.00 to $9.00. On average, they predict the company's share price to reach $8.50 in the next year. This suggests a possible upside of 220.8% from the stock's current price.
View analysts price targets for TRVI
or view top-rated stocks among Wall Street analysts.

How have TRVI shares performed in 2024?

Trevi Therapeutics' stock was trading at $1.34 at the beginning of 2024. Since then, TRVI stock has increased by 97.8% and is now trading at $2.65.
View the best growth stocks for 2024 here
.

When is Trevi Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our TRVI earnings forecast
.

How were Trevi Therapeutics' earnings last quarter?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) announced its quarterly earnings results on Wednesday, March, 20th. The company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.02.

What ETF holds Trevi Therapeutics' stock?

Simplify Propel Opportunities ETF holds 200,000 shares of TRVI stock, representing 0.58% of its portfolio.

What other stocks do shareholders of Trevi Therapeutics own?
When did Trevi Therapeutics IPO?

Trevi Therapeutics (TRVI) raised $70 million in an initial public offering on Tuesday, May 7th 2019. The company issued 4,700,000 shares at $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets served as the underwriters for the IPO and Needham & Company was co-manager.

How do I buy shares of Trevi Therapeutics?

Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TRVI) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners